TGNA:FRA
Transgene SA
0,68 €
arrow_upward
+1,50%(+0,0100) 1 D
12. okt., 08:08:13 GMT+2 · EUR
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for TGNA …
Åpne
0,68 €
Høy
0,68 €
Lav
0,68 €
Markedsverdi
193,88 mill.
Snittvolum
0,00
Volum
0,00
52 u høy
1,48 €
52 u lav
0,60 €
EPS
−0,17 €
Antall ansatte
152
Åpne
0,68 €
Høy
0,68 €
Lav
0,68 €
Markedsverdi
193,88 mill.
Snittvolum
0,00
Volum
0,00
52 u høy
1,48 €
52 u lav
0,60 €
EPS
−0,17 €
Antall ansatte
152
Nyhetssaker
Fra nettkilder og nyhetspartnere
Invezz
·
for 2 døgn siden
Dow stiger 423 poeng etter teknologireprise, telekomaksjer faller på SpaceX
Invezz
·
for 4 timer siden
Topp 3 katalysatorer for S&P 500-indeksen denne uken: obligasjoner, kvartalstall, KPI
巴士的報
·
for 25 minutter siden
SSA Commissioner Headlines Columbus Day at the NYSE: NYSE Content Update
Foreign Policy Journal
·
for 11 minutter siden
SoundHound AI (NASDAQ: SOUN) Slides 46% In 2026 As Cash Burn Outpaces Revenue Growth
Profil
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
Om Transgene SA